Table 6.
Melanomas. Adjuvant treatment with nonspecific immune stimulants. Randomised studies [20].
| Authors | No. of cases | Stage | Treatment | Followup (years) | Statistical significance |
|---|---|---|---|---|---|
| Balch 1982 | 260 | III | C. parvum | 2 y. | NS |
| Paterson 1984 | 199 | I-II | BCG | 4 y. | NS |
| Miller 1988 | 168 | II-III | Transfer factor | 2 y. | NS |
| Observation | |||||
| Lipton 1991 | 262 | C. parvum | 4–9 y. | CS | |
| BCG | |||||
| Quirt 1991 | 577 | I-IIA-IIB | Levamisole | ||
| BCG | |||||
| BCG + Levamisole | |||||
| Observation | |||||
| Spitler 1991 | 216 | I-IIA-IIB-III-IV | Levamisole | 10 y. | NS |
| Observation | |||||
| Czarnetzki 1993 | 353 | II | BCG (RIV) | 6 y. | NS |
| BCG (Pasteur) | |||||
| Observation |
CS: close to significance. NS: not significant.